Onward Medical NV (ONWDB.XD), on Wednesday announced the first human implant of its investigational ARC-IM Lumbar Lead on March 17, 2025.
This milestone procedure, performed by Dr. Jocelyne Bloch at Lausanne University Hospital in Switzerland, marks a significant step in the company's development of spinal cord stimulation therapies for restoring movement and function in people with spinal cord injuries or SCI.
The ARC-IM Lumbar Lead is designed for use in the lumbar region of the spinal cord, targeting the restoration of standing, stepping, and lower limb mobility.
It is part of ONWARD's portfolio of purpose-designed leads aimed at optimizing the delivery of ARC-IM Therapy.
This therapy is being studied in clinical feasibility studies, with and without an implanted brain-computer interface or BCI.
This follows the company's previous first-in-human use of the ARC-IM Thoracic Lead in 2023, which was optimized for the thoracic region and is being used in studies for addressing blood pressure instability in SCI patients.
Currently, ONWDB.XD is trading at $4.88 down by 1.11%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.